Chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies are transforming multiple myeloma care, with earlier use, expanded community access, and outpatient delivery models offering ...
FDA approval criteria primarily dictate the sequencing of multiple myeloma therapies, often restricting bispecific antibodies to later treatment lines. Institutional practices vary in using CAR T-cell ...
A laboratory study out of Roswell Park Comprehensive Cancer Center outlines a new way to boost the effectiveness of chimeric antigen receptor (CAR) T-cell therapy in solid-tumor cancers, resulting in ...
CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has revolutionized how physicians treat cancer, especially blood cancers. “These patients can be cured ...
Ever since 6-year-old Emily Whitehead became the first pediatric patient to receive CAR-T cell therapy in 2012, when T cells were removed from her body and reprogrammed to attack her leukemia before ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. An mRNA‑based CAR T therapy called Descartes‑08 is giving many people with myasthenia gravis ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients with systemic lupus erythematosus who received ...
Please provide your email address to receive an email when new articles are posted on . Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly ...
As demand for precision medicine accelerates, CAR T and CAR Treg cell therapies are emerging as crucial tools in the fight against cancer and autoimmune diseases. For Thomas Fellner, PhD, head of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results